Resources
Practice resources
Product Information, patient education materials, and other resources.
Patient Information
Patient information on Multiple Myeloma, Products, and patient resources like financial support and and copay cards.
Myeloma News
Powered By:
- EC Approves New Sarclisa Indication
- Four Drugs Upfront Yield ‘Unprecedented’ Response in Myeloma
- European Commission Approves Second Indication Of Sarclisa® (Isatuximab) For Relapsed Multiple Myeloma
- Studies Suggest People with Blood Cancers May Not Be Optimally Protected after COVID-19 Vaccination
- Personalized Cancer Vaccine Given After Adjuvant Therapy Safe, Shows Early Efficacy in Multiple Tumor Types
- Molecular Templates to Prioritize Next-Generation ETB Candidates
- SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and Janssen’s BCMA Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
- FDA Approves Isatuximab-Irfc For Multiple Myeloma
- FDA Approves Sarclisa® (Isatuximab) in Combination With Carfilzomib And Dexamethasone For Patients With Relapsed or Refractory Multiple Myeloma
- International Myeloma Foundation Says FDA Approval of Bristol Myers Squibb’s and bluebird bio’s CAR T-Cell Immunotherapy Treatment for Multiple Myeloma Is Welcome News for Patients